نتایج جستجو برای: ingenol mebutate
تعداد نتایج: 232 فیلتر نتایج به سال:
AK: actinic keratosis BCCs: basal cell carcinomas FD: field directed LD: lesion directed NMSC: nonmelanoma skin cancer OTRs: organ transplant recipients PDT: photodynamic therapy SCCs: squamous cell carcinomas UV: ultraviolet INTRODUCTION Field cancerization in organ transplant recipients (OTRs) is a frequent occurrence, setting the stage for multiple squamous cell carcinomas (SCCs). Immunosupp...
Skin cancer is the most common cancer in the USA. Non-melanoma skin cancers, which include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), comprise the majority. BCC and SCC are commonly treated with surgical excision, curettage, cryotherapy and radiation. Actinic keratoses (AK) are considered precursors of SCC and are commonly treated with 5-fluorouracil, imiquimod, diclofenac, l...
The diterpenoid ester ingenol mebutate (IngMeb) is the active ingredient in the topical drug Picato, a first-in-class treatment for the precancerous skin condition actinic keratosis. IngMeb is proposed to exert its therapeutic effects through a dual mode of action involving (i) induction of cell death that is associated with mitochondrial dysfunction followed by (ii) stimulation of a local infl...
Actinic keratosis (AK) is a common dermatologic diagnosis with the potential of malignant transformation. Treatment options include destructive therapies, such as cryotherapy, and topical medications, 5-fluorouracil (5-FU), imiquimod, ingenol mebutate. Historically, procedures have remained standard care. There been limited updates on AK management practices; we determined frequency procedural ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید